Erdanib 4 mg (Erdafitinib) is a targeted therapy used for metastatic urothelial carcinoma with FGFR mutations. It inhibits abnormal cancer cell growth. Common side effects include eye problems, dry mouth, diarrhea, and increased phosphate levels. Regular monitoring is essential. https://www.jkmedicine.com/product/details/97